Klotho Neurosciences Reports Director/Officer Changes & Financials

Ticker: GRMLW · Form: 8-K · Filed: Nov 25, 2024 · CIK: 1907223

Sentiment: neutral

Topics: management-change, financials, corporate-action

Related Tickers: KLTO

TL;DR

Klotho Neurosciences (KLTO) filed an 8-K detailing director/officer changes and financial updates.

AI Summary

Klotho Neurosciences, Inc. filed an 8-K on November 25, 2024, reporting events as of November 19, 2024. The filing pertains to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. It also includes financial statements and exhibits. The company was formerly known as ANEW Medical, Inc. and Redwoods Acquisition Corp.

Why It Matters

This filing indicates potential shifts in the company's leadership and governance, which could impact strategic direction and operational execution.

Risk Assessment

Risk Level: medium — Changes in directors and officers, along with the filing of financial statements, can signal significant internal developments that may affect the company's future performance.

Key Players & Entities

FAQ

What specific changes occurred regarding directors or officers?

The filing indicates events related to the departure of directors or certain officers, election of directors, and appointment of certain officers, as well as compensatory arrangements for certain officers.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this filing was on November 19, 2024.

What is the filing date of this 8-K?

This 8-K filing was made on November 25, 2024.

What were Klotho Neurosciences, Inc.'s former names?

Klotho Neurosciences, Inc. was formerly known as ANEW Medical, Inc. and Redwoods Acquisition Corp.

What are the main items covered in this 8-K filing?

This 8-K filing covers changes in directors/officers, elections, appointments, compensatory arrangements, and includes financial statements and exhibits.

Filing Stats: 866 words · 3 min read · ~3 pages · Grade level 11.2 · Accepted 2024-11-25 17:09:08

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 25, 2024 KLOTHO NEUROSCIENCES, INC. By: /s/ Joseph Sinkule Name: Joseph Sinkule Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing